OKYO Pharma Limited (EMMLF)
OKYO Pharma Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in London, GB. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $22.7M. On trailing twelve-month figures it carries a trailing P/E of -6.40, a net margin of 0.0%. Its beta of -0.06 implies it has historically moved less than the broad market.
OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide analogue sourced from bovine adrenal medulla, intended for the management of neuropathic ocular pain. Founded in 2007, OKYO Pharma Limited is headquartered in London, United Kingdom.
OKYO Pharma Limited is most often compared with the following Healthcare names: